Another study identified PTHrP (12–48) as a predictive biomarker of breast cancer bone metastasis such that levels of the peptide were significantly increased in the plasma of patients with clinical evidence of bone metastases versus patients without [55]. Here, PTHLH is linked to bone metastasis.